

Issue number: Version 1 (enter number)

Subject: Management of Hypokalaemia

Objective: To describe the appropriate management of hypokalaemia in hospitalised patients in non-critical areas of Trust

Target Level: Trust-Wide

Prepared by: **Vinita Mishra (Consultant Chemical Pathologist)**
James Baker (Advanced Pharmacist – Clinical Nutrition)
John Bassett (SpR Clinical Biochemistry)

Evidence Base: Rank: A, B, C or D (CSG/CG Dept will categorise evidence base) **'CG Approved' logo will be added by CG Dept.**

Associated Documents: Outline other documents that this document should be read in conjunction with or may be required for implementation of this clinical guideline (If appropriate).

Information Classification Label

Unclassified

Date of Issue: September 2021

Review Date: month & year + 3

REVIEW HISTORY			
Issue No.	Page	Changes made with rationale and impact on practice	Date

Purpose of Guideline:


This describes the appropriate management of hypokalaemia in hospitalised patients. Hypokalaemia is defined as serum potassium <3.5mmol/L.

Severe hypokalaemia is defined as serum potassium of ≤2.5 mmol/L.

Most patients with hypokalaemia will be asymptomatic. The most common serious consequence of hypokalaemia is cardiac arrhythmias. The severe hypokalaemia can present with flaccid paralysis, hyporeflexia, muscle weakness and respiratory depression. Potassium levels below 2mmol/l may result in rhabdomyolysis.

This guidance only for wards and emergency medicine.

Treatment Algorithm:



***All of these patients should be managed in a monitored bed until their electrolyte balance has resolved. Please look for and treat other metabolic abnormalities.**

Please contact on call endocrinology or on call biochemist (through switch board) to ensure plan and prescription is appropriate.

Finding the cause

Finding the cause:

To successfully treat hypokalaemia it is important to know the cause. Causes of hypokalaemia can be broadly split into 4 categories – insufficient intake, intracellular shift, gastrointestinal loss and renal losses.

Insufficient intake	Intracellular shift	Gastrointestinal losses	Renal losses
Alcohol excess	Alcohol excess (alcoholic ketogenesis)	Alcohol excess	Alcohol excess (kaliuresis)
Anorexia nervosa	Insulin administration	Diarrhoea	DKA
Ketogenic diet	Alkalosis	Excessive sweating	Medications (loop diuretics, thiazide diuretics, amphotericin, cisplatin)
	Use of beta agonists	Muscle crush injuries	Hypomagnesaemia
	Use of theophylline / aminophyllin	Pancreatic fistula	Hyperaldosteronism
	Defect of muscular ion channels (eg. Hypokalaemic periodic paralysis)	Vomiting / Nasogastric tube losses	Cushing's
	Refeeding syndrome		Barter's syndrome
			Gitelman's syndrome

Discharge advice:

1. Patients being discharged with hypokalaemia or on hypokalaemia treatment should not go home with more than 2 days of therapy.
2. GP should be advised to recheck potassium if potassium supplementation is expected to take place over long period.
3. If chronic potassium replacement is required, a long term follow up plan with at least weekly potassium tests in the community must be put into place.

CHRONIC HYPOKALAEMIA IS RARE: ALL PATIENTS WHO ARE CONSIDERED TO HAVE THIS DIAGNOSIS SHOULD HAVE BEEN INVESTIGATED BY EITHER GASTROENTEROLOGY, RENAL OR ENDOCRINOLOGY AND BE UNDER THE APPROPRIATE TEAMS' LONG TERM FOLLOW UP. REFERRAL IS DEPENDENT ON PATIENT SYMPTOMS.

References

Mishra V. Hypokalaemia. Royal Liverpool University Hospitals Foundation Trust. March 2018.

Halperin, ML; Kamel, KS (1998). "Potassium". *Lancet*. 352 (9122): 135–40. doi:10.1016/S0140-6736(98)85044-7. PMID 9672294. S2CID 208790031

Acknowledgement